Dr. Fatima Cody Stanford

Weighing the GLP-1 Market

Dr. Fatima Cody Stanford, Jonathan Gruber, Alison Nathan

Experts and economists convened to analyze the clinical efficacy of GLP-1 agonists for obesity, contrasting their maximum 22.5% weight reduction rates against the superior remission capabilities of bariatric surgery and the 20% non-response rate observed in diverse patient cohorts. The discussion highlighted systemic barriers where Medicare excludes obesity coverage while private plans vary, driving debates on pricing models and the potential $800 billion annual economic impact of widespread adoption. Ultimately, the dialogue proposed policy interventions such as government price adjudication and prize-based incentives to balance pharmaceutical innovation incentives with public affordability and workforce productivity gains.